Reported 3 days ago
Shares of WuXi AppTec and WuXi Biologics soared after a proposed US legislation that could have limited their roles in drug development missed its final opportunity for passage this year. The absence of the Biosecure Act from the National Defense Authorization Act is seen as a significant relief for these companies, which faced potential barriers to federally-funded contracts. Despite a turbulent legislative journey, current analysts view this situation positively, suggesting that the implications for WuXi firms are favorable in the near term.
Source: YAHOO